New York, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) — Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight
The exosome market is fueled by several significant factors, such as the rising incidence of chronic diseases, improvements in diagnostic methods, and heightened interest in personalized medicine. Exosomes’ potential as biomarkers for numerous conditions adds to their value in research and clinical settings. Moreover, growing investments in the biotech and pharmaceutical sectors, coupled with partnerships between academic and commercial organizations, are further accelerating market expansion.
DelveInsight’s Exosome Market Insights report provides the current and forecast market analysis, individual leading Exosome companies’ market shares, challenges, Exosome market drivers, barriers, trends, and key market Exosome companies in the market.
Key Takeaways from the Exosome Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global Exosome market during the forecast period.
- In the product type segment of the exosome market, the kits and reagents category is projected to capture a substantial revenue share in the coming years.
- Notable Exosome companies such as Danaher, Thermo Fisher Scientific Inc., QIAGEN, Hologic, Bio-Techne., Takara Bio Inc., FUJIFILM Corporation, Miltenyi Biotec, Lonza., JSR Corporation., System Biosciences, LLC., Malvern Panalytical Ltd., Norgen Biotek Corp., Cell Guidance Systems Ltd., and several others, are currently operating in the Exosome market.
- In July 2024, Aruna Bio announced the issuance of a US Patent for the composition of matter for neural exosomes used to deliver therapeutics to the brain. The company is on a rack to initiate Phase Ib/IIa clinical trial of AB126 in acute ischemic stroke in the second half of 2024.
- In July 2024, ILIAS Biologics announced that they have received the final clinical study report (CSR) for ILB-202, from a Phase I clinical trial completed in Australia in November last year.
- In April 2024, Biological Dynamics joined the growing list of customers adopting the ExoVerita Pro instrument, a cost-efficient, automated exosomal enrichment platform.
- In April 2024, EXO Biologics secures up to EUR 16 million in Series A funding for exosome therapeutic development and clinical supply.
- In April 2024, ExoXpert entered a strategic partnership with Neucore Bio to leverage ExoXpert’s platform for the evaluation of advanced exosome loading.
- In April 2024, INOVIQ and Promega signed a global supply and distribution agreement for EXO-NET. Last year’s company entered into a Co-Marketing agreement.
- In March 2024, VivaZome Therapeutics and La Trobe University collaborated to explore the therapeutic potential of extracellular vesicles in models of stroke in the laboratory of Professor Chris Sobey.
To read more about the latest highlights related to the exosome market, get a snapshot of the key highlights entailed in the Global Exosome Market Report
Exosome Overview
Exosomes are small, membrane-bound extracellular vesicles secreted by various cell types that play a crucial role in cell communication. Measuring approximately 30–150 nanometers, they are formed within the endosomal compartment of cells and released into the extracellular space when multivesicular bodies fuse with the plasma membrane. Exosomes contain a rich variety of biomolecules, including proteins, lipids, RNA, and DNA, making them vital for transmitting biological information. Due to their small size and ability to carry molecular cargo, exosomes are involved in a wide range of physiological processes, including immune response, tissue repair, and intercellular signaling. Their release is often enhanced in response to cellular stress or damage, suggesting a role in disease processes, particularly in cancer, cardiovascular diseases, and neurodegenerative disorders.
In therapeutic contexts, exosomes offer promising applications due to their natural ability to transport biological molecules between cells. Researchers are exploring their potential as targeted delivery vehicles in regenerative medicine, immunotherapy, and cancer treatment. For instance, exosomes can be engineered to carry therapeutic RNA or drugs directly to specific cells, minimizing off-target effects and enhancing therapeutic efficacy. Additionally, their biocompatibility and low immunogenicity make them an attractive alternative to synthetic delivery systems. However, challenges in standardizing exosome isolation, characterization, and large-scale production need to be addressed before their full clinical potential can be realized. As research advances, exosomes could become a powerful tool in precision medicine, offering targeted, efficient, and patient-specific treatment options.
Exosome Market Insights
In 2023, North America held the largest share of the exosome market, primarily due to several influential factors, including the growing incidence of chronic conditions such as cancer in the region. The strong foundation of research and development infrastructure and the presence of major biotech and pharmaceutical firms contribute to favorable conditions for exosome-related products. This dynamic environment supports new product development and launches, fueling further growth in the North American exosome market.
Moreover, collaborations among industry leaders are enhancing the market’s growth potential. For example, in October 2023, Cytiva partnered with RoosterBio, Inc. to develop a purification process for the large-scale production of exosomes. This collaboration leverages the expertise of both companies to tackle significant challenges that currently limit the therapeutic use of exosomes, including their application as delivery systems for gene therapies and biologics.
Increased investment in exosome R&D is also driving innovation in the sector, with academic institutions, research organizations, and private enterprises focusing on the unique properties of exosomes, such as their role in intercellular communication and potential uses in regenerative medicine, drug delivery, and biomarker discovery.
The convergence of these elements—high cancer rates, robust R&D, strategic partnerships, and a growing interest in exosome applications—positions North America as a leader in the exosome market. As awareness and recognition of exosome technology grow, the market is projected to expand significantly during the forecast period, highlighting North America’s pivotal role in advancing exosome research and its clinical applications.
To know more about why North America is leading the market growth in the exosome market, get a snapshot of the Exosome Market Outlook
The exosome market has been experiencing dynamic growth, fueled by increasing interest in its therapeutic, diagnostic, and research applications. The rapid expansion of research activities, coupled with advancements in biotechnology, has created a promising ecosystem for companies aiming to harness exosomes’ therapeutic benefits.
The therapeutic potential of exosomes is a major driver in the market, as these vesicles offer a natural, less immunogenic alternative to synthetic nanoparticles for drug delivery. Pharmaceutical companies and biotech firms are actively exploring exosome-based drug delivery systems, targeting specific cells and tissues with high precision. Notably, the role of exosomes in regenerative medicine and gene therapy has sparked significant interest. Their capability to cross biological barriers, such as the blood-brain barrier, makes them an attractive candidate for delivering therapeutic agents in neurological diseases, positioning exosomes as a novel tool in personalized medicine.
Another critical factor shaping the exosome market is the rising demand for exosome-based diagnostics. Exosomes are found in various body fluids, making them accessible biomarkers for liquid biopsies, which provide non-invasive diagnostic and monitoring options. This application is particularly valuable in cancer, where exosome-based tests can provide real-time insights into tumor progression, treatment response, and relapse. With increasing awareness about early diagnosis and minimally invasive procedures, diagnostic companies are investing in exosome technology to enhance their product offerings, propelling growth in this segment of the market.
However, the exosome market is not without its challenges. One of the major constraints is the complexity and cost of exosome isolation and purification. Despite technological advancements, developing standardized protocols for exosome extraction and characterization remains a significant hurdle, impacting scalability and cost-effectiveness. Additionally, regulatory uncertainties around exosome-based products can slow down their clinical translation, as regulatory agencies have yet to establish comprehensive guidelines for exosome therapies and diagnostics. These challenges underline the need for industry collaboration and innovation to address technical and regulatory barriers.
Looking ahead, the exosome market is likely to witness continued expansion, driven by partnerships, research collaborations, and investment in R&D. As companies work towards overcoming the technical challenges of exosome production and regulation, the market’s growth potential remains robust. In the coming years, with improvements in exosome engineering, purification, and clinical application strategies, exosomes could become a cornerstone technology in precision medicine, potentially revolutionizing therapeutic and diagnostic approaches across multiple medical fields.
Get a sneak peek at the exosome market dynamics @ Exosome Market Dynamics Analysis
| Report Metrics | Details |
| Coverage | Global |
| Study Period | 2021–2030 |
| Exosome Market CAGR | ~20% |
| Key Exosome Companies | Danaher, Thermo Fisher Scientific Inc., QIAGEN, Hologic, Bio-Techne., Takara Bio Inc., FUJIFILM Corporation, Miltenyi Biotec, Lonza., JSR Corporation., System Biosciences, LLC., Malvern Panalytical Ltd., Norgen Biotek Corp., Cell Guidance Systems Ltd., among others |
Exosome Market Assessment
- Exosome Market Segmentation
- Exosome Market Segmentation By Product Type: Kits & Reagents and Instruments
- Exosome Market Segmentation By End Users: Pharmaceutical Companies and Research Organizations
- Exosome Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
- Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
Which MedTech key players in the exosome market are set to emerge as the trendsetter explore @ Exosome Companies
Table of Contents
| 1 | Exosome Market Report Introduction |
| 2 | Exosome Market Executive Summary |
| 3 | Competitive Landscape |
| 4 | Regulatory Analysis |
| 5 | Exosome Market Key Factors Analysis |
| 6 | Exosome Market Porter’s Five Forces Analysis |
| 7 | Exosome Market Layout |
| 8 | Exosome Market Company and Product Profiles |
| 9 | KOL Views |
| 10 | Project Approach |
| 11 | About DelveInsight |
| 12 | Disclaimer & Contact Us |
Interested in knowing the exosome market by 2030? Click to get a snapshot of the Exosome Market Trends
Related Reports
Exosome Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key exosome therapies companies, including Direct Biologics, Capricor Therapeutics, Aegle Therapeutics, Vitti Labs, Rion, Aruna Bio, EXO Biologics, EV Therapeutics, ReNeuron, Coya Therapeutics, Evox Therapeutics, among others.
Exosome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, Exostemtech, Brexogen, OmniSpirant, ShiftBio Inc., among others.
Duchenne Muscular Dystrophy Market
Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DMD companies, including FibroGen, Santhera Pharmaceutical, Italfarmaco, ReveraGen BioPharma, Cumberland Pharmaceuticals, Sarepta Therapeutics, Antisense Therapeutics, Capricor Therapeutics, among others.
Duchenne Muscular Dystrophy Pipeline
Duchenne Muscular Dystrophy Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Duchenne muscular dystrophy companies, including Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics, among others.
Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies, including Arcutis Biotherapeutics, Amgen, Kyowa Kirin, Dermavant Sciences, Cara Therapeutics, Pfizer, Arena Pharmaceuticals, BioMimetix, Eli Lilly and Company, Aldeyra Therapeutics, Inc., Hangzhou Yirui Pharmaceutical Technology Co., Ltd, LEO Pharma, Corvus Pharmaceuticals, Inc., Brexogen Inc., Sanofi, Shaperon, UCB Pharma, Q32 Bio Inc., Akeso, Apogee Therapeutics, Inc., Allakos Inc., Biosion, Inc., among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Consulting Services
Healthcare Conference Coverage
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
